AR049712A1 - DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE PI3K; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO CON EFECTO ANTI-PROLIFERATIVO. - Google Patents
DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE PI3K; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO CON EFECTO ANTI-PROLIFERATIVO.Info
- Publication number
- AR049712A1 AR049712A1 ARP050102852A ARP050102852A AR049712A1 AR 049712 A1 AR049712 A1 AR 049712A1 AR P050102852 A ARP050102852 A AR P050102852A AR P050102852 A ARP050102852 A AR P050102852A AR 049712 A1 AR049712 A1 AR 049712A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- alkyl
- ureido
- amino
- group
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 51
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 46
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 24
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 16
- -1 nitro, hydroxy, mercapto, amino, formyl Chemical group 0.000 abstract 15
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 12
- 125000005281 alkyl ureido group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 6
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 6
- 125000004423 acyloxy group Chemical group 0.000 abstract 6
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 125000001589 carboacyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 5
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 3
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 abstract 2
- 125000006323 alkenyl amino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- BWOVZCWSJFYBRM-UHFFFAOYSA-N carbononitridic isocyanate Chemical compound O=C=NC#N BWOVZCWSJFYBRM-UHFFFAOYSA-N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0415367.2A GB0415367D0 (en) | 2004-07-09 | 2004-07-09 | Pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049712A1 true AR049712A1 (es) | 2006-08-30 |
Family
ID=32865684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102852A AR049712A1 (es) | 2004-07-09 | 2005-07-08 | DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE PI3K; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO CON EFECTO ANTI-PROLIFERATIVO. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080051401A1 (enExample) |
| EP (1) | EP1778681A1 (enExample) |
| JP (1) | JP2008505877A (enExample) |
| KR (1) | KR20070032810A (enExample) |
| CN (1) | CN101010317A (enExample) |
| AR (1) | AR049712A1 (enExample) |
| AU (1) | AU2005261555A1 (enExample) |
| BR (1) | BRPI0513056A (enExample) |
| CA (1) | CA2571756A1 (enExample) |
| GB (1) | GB0415367D0 (enExample) |
| IL (1) | IL180138A0 (enExample) |
| MX (1) | MX2007000118A (enExample) |
| NO (1) | NO20070681L (enExample) |
| RU (1) | RU2007104838A (enExample) |
| TW (1) | TW200618801A (enExample) |
| UY (1) | UY29009A1 (enExample) |
| WO (1) | WO2006005918A1 (enExample) |
| ZA (1) | ZA200700060B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| GB0525081D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525080D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| KR20080083188A (ko) * | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| US20090325957A1 (en) * | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008023159A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008032041A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
| WO2009007750A1 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| WO2011080568A2 (en) * | 2009-12-28 | 2011-07-07 | Development Center For Biotechnology | Novel pyrimidine compounds as mtor and p13k inhibitors |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| FR2994572B1 (fr) * | 2012-08-17 | 2015-04-17 | Centre Nat Rech Scient | Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique |
| CA2903979A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CN111566086B (zh) * | 2018-01-04 | 2023-08-01 | 北京大学深圳研究生院 | 同时抑制lsd1和hdac靶点的化合物及其应用 |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| WO2025255134A1 (en) * | 2024-06-04 | 2025-12-11 | Soley Therapeutics, Inc. | Piperazinone based modulators for the treatment of disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
-
2004
- 2004-07-09 GB GBGB0415367.2A patent/GB0415367D0/en not_active Ceased
-
2005
- 2005-07-07 CA CA002571756A patent/CA2571756A1/en not_active Abandoned
- 2005-07-07 BR BRPI0513056-5A patent/BRPI0513056A/pt not_active Application Discontinuation
- 2005-07-07 US US11/630,676 patent/US20080051401A1/en not_active Abandoned
- 2005-07-07 CN CNA2005800297623A patent/CN101010317A/zh active Pending
- 2005-07-07 WO PCT/GB2005/002678 patent/WO2006005918A1/en not_active Ceased
- 2005-07-07 JP JP2007519885A patent/JP2008505877A/ja active Pending
- 2005-07-07 EP EP05759085A patent/EP1778681A1/en not_active Withdrawn
- 2005-07-07 RU RU2007104838/04A patent/RU2007104838A/ru not_active Application Discontinuation
- 2005-07-07 MX MX2007000118A patent/MX2007000118A/es not_active Application Discontinuation
- 2005-07-07 AU AU2005261555A patent/AU2005261555A1/en not_active Abandoned
- 2005-07-07 KR KR1020077003207A patent/KR20070032810A/ko not_active Withdrawn
- 2005-07-08 TW TW094123251A patent/TW200618801A/zh unknown
- 2005-07-08 UY UY29009A patent/UY29009A1/es not_active Application Discontinuation
- 2005-07-08 AR ARP050102852A patent/AR049712A1/es unknown
-
2006
- 2006-12-17 IL IL180138A patent/IL180138A0/en unknown
-
2007
- 2007-01-02 ZA ZA200700060A patent/ZA200700060B/en unknown
- 2007-02-06 NO NO20070681A patent/NO20070681L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200700060B (en) | 2008-06-25 |
| UY29009A1 (es) | 2006-02-24 |
| GB0415367D0 (en) | 2004-08-11 |
| CA2571756A1 (en) | 2006-01-19 |
| AU2005261555A1 (en) | 2006-01-19 |
| EP1778681A1 (en) | 2007-05-02 |
| BRPI0513056A (pt) | 2008-04-22 |
| JP2008505877A (ja) | 2008-02-28 |
| TW200618801A (en) | 2006-06-16 |
| WO2006005918A1 (en) | 2006-01-19 |
| CN101010317A (zh) | 2007-08-01 |
| MX2007000118A (es) | 2007-03-09 |
| KR20070032810A (ko) | 2007-03-22 |
| IL180138A0 (en) | 2007-06-03 |
| RU2007104838A (ru) | 2008-08-27 |
| US20080051401A1 (en) | 2008-02-28 |
| NO20070681L (no) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051215A1 (es) | Derivados de quinazolina | |
| AR033560A1 (es) | Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento, | |
| AR061132A1 (es) | Compuestos de fenilalanina, alanina y tirosina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la integrina alfa5beta1. | |
| AR054612A1 (es) | Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| PE20080671A1 (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
| AR059716A1 (es) | Derivados de quinolina | |
| AR069772A1 (es) | Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria. | |
| AR069078A1 (es) | Derivados de piridina y pirazina | |
| AR041189A1 (es) | Piridinas y pirimidinas condensadas con actividad anti-angiogenica, que actuan sobre el receptor de tirosina quinasa | |
| AR039203A1 (es) | Derivados de quinazolina | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR045762A1 (es) | Derivados de quinazolina | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR070573A1 (es) | Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamento | |
| AR051738A1 (es) | Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos | |
| AR066348A1 (es) | Inhibidores de las iap | |
| AR064246A1 (es) | Derivados de 5h-pirimido[5,4-d][2]benzazepinas inhibidores de la progresion mitotica,composiciones farmaceuticas que los contienen y usos como agentes anticancer. | |
| AR083200A1 (es) | Compuestos de n-heteroarilo | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| PA8592001A1 (es) | Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| UY29009A1 (es) | Nuevos derivados de pirimidina, sales y solvatos farmaccuticamente aceptables de los mismos, composiciones, procedimientos para su preparacinn y uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |